Market Closed - Nasdaq Stockholm 09:30:00 27/06/2024 pm IST 5-day change 1st Jan Change
3.82 SEK +6.56% Intraday chart for Q-linea AB -3.29% +3.24%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Q-Linea AB Receives Another Commercial Order in Italy CI
Transcript : Q-linea AB, Q1 2024 Earnings Call, May 31, 2024
Q-linea AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Q-Linea AB Offers an Extended Loan Facility by the Main Shareholder Nexttobe CI
Q-linea AB Announces Change of Earnings Results Date for the First Quarter 2024 CI
Q-linea AB Signs Evaluation Contract with Reference Laboratory Network in the US CI
Q-Linea AB Receives FDA 510(k) Clearance for the ASTar® System CI
Q-linea AB Presents Strong ASTar Results At AMCLI CI
Transcript : Q-linea AB, Q4 2023 Earnings Call, Feb 27, 2024
Q-linea AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Q-linea AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Q-linea Presents at AMCLI CI
Q-linea to Develop Diagnostic Product Podler Via Separate Subsidiary MT
Q-Linea AB Appoints Anders Ljunggren as Managing Director, Effective 1 March 2024 CI
Q-linea Lands First ASTar Order from Finnish Distributor MT
Q-Linea AB Receives an Order for an ASTar System CI
Q-linea to Cut 40 Jobs in Cost Savings Program MT
Q-linea AB Announces CEO Changes CI
Q-linea AB Expands the Gram-Negative Panel CI
Q-Linea Wins Public Tender for Rapid AST CI
Q-linea Installs First ASTar Systems in US; Shares Jump MT
Q-linea Signs Distribution Deal for Benelux Region with Biomedical Diagnostics MT
Transcript : Q-linea AB, Q3 2023 Earnings Call, Nov 02, 2023
Q-linea AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Sweden's Q-linea Partners with Labema to Boost Presence in Finland, Baltic States MT
Chart Q-linea AB
More charts
Q linea AB is a Sweden-based medical technology company. The Company develops and manufactures in-vitro diagnostic (IVD) solutions for infectious diseases. The Company's core product candidate is ASTar, a fully-automated instrument for Antibiotic Susceptibility Testing (AST). It measures bacteria's antimicrobial susceptibility using the disposables developed by the Company. It is able to provide a susceptibility profile within three to six hours directly from a positive blood culture, which enables early administration of antibiotics specifically targeting the disease-causing pathogen. Its main application is the identification of sepsis in hospital patients and the product is aimed primarily at hospital laboratories.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
  1. Stock Market
  2. Equities
  3. QLINEA Stock
  4. News Q-linea AB
  5. Sweden's Q-linea Partners with Labema to Boost Presence in Finland, Baltic States